First-in-Class CDK4/6 Inhibitor Palbociclib Could Usher in a New Wave of Combination Therapies for HR+, HER2- Breast Cancer.

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med (2011) 13.74

Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol (2007) 6.11

Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther (2004) 5.69

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol (2014) 5.31

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res (2009) 5.20

Prognostic and predictive factors in early-stage breast cancer. Oncologist (2004) 2.84

Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Mol Cancer Ther (2011) 2.73

The past, present, and future of cancer incidence in the United States: 1975 through 2020. Cancer (2015) 2.63

US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst (2014) 2.17

Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†. Ann Oncol (2014) 1.95

Molecular pathways: CDK4 inhibitors for cancer therapy. Clin Cancer Res (2014) 1.44

Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial. Cancer (2013) 1.37

Signaling through cyclin D-dependent kinases. Oncogene (2013) 1.27

Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine. Invest New Drugs (2014) 1.26

Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy. J Clin Oncol (2011) 1.02

The cancer drug that almost wasn't. Science (2014) 0.96

Incorporating genomics into breast cancer clinical trials and care. Clin Cancer Res (2013) 0.85

The MAPK (ERK) Pathway: Investigational Combinations for the Treatment Of BRAF-Mutated Metastatic Melanoma. P T (2013) 1.68

Renewing the assault on mRNA. Biotechnol Healthc (2004) 0.81

The cancer genome atlas: new weapon in old war? Biotechnol Healthc (2006) 0.77

To Heal the Body, Get Into the Patient's Head: Motivational Interviewing: To improve adherence. Biotechnol Healthc (2012) 0.75

Drugs that offer a survival advantage for men with bone metastases resulting from castration-resistant prostate cancer: new and emerging treatment options. P T (2014) 0.75

Kenneth tanabe works to solve the mysteries of liver cancer: while progress has been relatively slow, this noted expert sees reasons for hope. P T (2015) 0.75

Carlos Fernández-del Castillo Confronts The Challenge of Pancreatic Cancer: Although Progress Has Been Slow, a Renowned Expert On the Disease Sees Reasons for Hope. P T (2014) 0.75

Doing more with less?: past and present challenges for the FDA. P T (2011) 0.75

Connecting Patients With Specialty Products: Part 2: The future of specialty drug distribution. Biotechnol Healthc (2012) 0.75

Does race have a place in biotechnological research? Biotechnol Healthc (2005) 0.75

William B. White Explains the Changes In the Way We Look at Blood Pressure: Which Numbers Matter Most-and Why Can They Be Deceptive? P T (2016) 0.75

P&T committees in position to reduce medication errors. Manag Care (2004) 0.75

When timing is of the essence. Biotechnol Healthc (2005) 0.75

Part 1: Distribution models for biologics and other specialty pharmaceutical products: In this first of a two-part series, we examine the distribution landscape for specialty pharmaceuticals. A manufacturer's strategy for the flow of product to patient has important implications for payers and for the success of a new biologic therapy. Biotechnol Healthc (2012) 0.75

The weight debate, continued. Manag Care (2004) 0.75

Could QALYs help in assessing high-priced cancer treatments? Manag Care (2013) 0.75

Chimeric Antigen Receptor T-Cell Therapy: The Next Big Thing Faces Challenges. Manag Care (2017) 0.75

Prediabetes: Pre- Does Not Mean Preordained. Manag Care (2016) 0.75

Flu's other cost. Manag Care (2005) 0.75

Hospital at home saves 19% in real-world study. Manag Care (2012) 0.75

Managed care (and everyone else) unprepared for the next killer flu. Manag Care (2005) 0.75

Shaking the tree of life. Biotechnol Healthc (2004) 0.75

The future of gene therapy. Biotechnol Healthc (2005) 0.75

Choosing the right oral antiplatelet medication. Manag Care (2013) 0.75

Health plans respond as microbes develop resistance techniques. Manag Care (2004) 0.75

Statin therapy: more than meets the eye? Manag Care (2004) 0.75

A Method to the mAbNESS? Biotechnol Healthc (2004) 0.75